What this is
- How it works
- How it works isn't classified yet
- Tested for
- Myotonic Dystrophy 1 (2 trials)
- Main trialPhase 2
- “The purpose of this study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.”In the company’s words, NCT06667453 on ClinicalTrials.gov
Other drugs for Myotonic Dystrophy 1
- TideglusibAMO Pharma Limited · Phase 2/3
- Mexiletine granulesLupin Ltd. · Phase 3
- Zeleciment basivarsenDyne Therapeutics · Phase 3
- AOC 1044Avidity Biosciences, Inc. · Phase 3
- Del-desiranAvidity Biosciences, Inc. · Phase 3
- Zeleciment RostudirsenDyne Therapeutics · Phase 3
Coming up2
- Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- Jan 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2027 | A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 | |
| Phase 2Recruiting | Jan 2029 | An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE) | |
| Phase 1Completed | 28 Oct 2025 | Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026